EVOLUS, INC. (EOLS) Gross Margin
- Gross margin · 12 months: Value 66.74%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 66.74% | Gross profit / revenue. Period ending 2026-06-30. $211.21M ÷ $316.49M × 100 ≈ 66.74% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 211.21M USD | Gross Profit |
| Revenue | 316.49M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 105.28M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $211.21M | $316.49M | $105.28M | 66.74% |
| 2026-03-31 | $199.35M | $301.79M | $102.44M | 66.06% |
| 2025-12-31 | $197.11M | $297.18M | $100.07M | 66.33% |
| 2025-09-30 | $190.45M | $285.82M | $95.37M | 66.63% |
| 2025-06-30 | $186.71M | $277.94M | $91.23M | 67.18% |
| 2025-03-31 | $188.46M | $275.46M | $87.01M | 68.41% |
| 2024-12-31 | $182.30M | $266.27M | $83.97M | 68.46% |
| 2024-09-30 | (m) | $248.33M | $74.64M | (m) |
| 2024-06-30 | (m) | $237.26M | $71.84M | (m) |
| 2024-03-31 | (m) | $219.70M | $67.48M | (m) |
| 2023-12-31 | (m) | $202.09M | $61.56M | (m) |
| 2023-09-30 | (m) | $184.73M | $55.66M | (m) |
| 2023-06-30 | (m) | $168.61M | $53.72M | (m) |
| 2023-03-31 | (m) | $156.43M | $54.83M | (m) |
| 2022-12-31 | (m) | $148.62M | $55.89M | (m) |
| 2022-09-30 | (m) | $139.63M | $58.35M | (m) |
| 2022-06-30 | (m) | $132.41M | $56.35M | (m) |
| 2022-03-31 | (m) | $121.34M | $51.83M | (m) |
| 2021-12-31 | (m) | $99.67M | $43.53M | (m) |
| 2021-09-30 | (m) | $85.59M | $34.98M | (m) |
| 2021-06-30 | (m) | $76.58M | $28.34M | (m) |
| 2021-03-31 | (m) | $58.28M | $18.99M | (m) |
| 2020-12-31 | (m) | $56.54M | $18.30M | (m) |
| 2020-09-30 | $40.75M | $55.41M | $14.66M | 73.55% |
| 2020-06-30 | $37.40M | $50.92M | $13.52M | 73.44% |
| 2020-03-31 | $33.19M | $45.42M | $12.23M | 73.07% |
| 2019-12-31 | $26.91M | $34.92M | $8.01M | 77.05% |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $0.00 | $0.00 | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |